

## Special Issue

# Management of MALT Lymphoma

### Message from the Guest Editor

Dear colleagues, This Special Issue on MALT-lymphoma will cover basic aspects (including pathology and recent developments in molecular and genetic features, especially site-specific differences) as well as diagnostics and therapy of this lymphoma entity. While the stomach has been the paradigm for MALT-lymphoma for decades, various differences between gastric vs non-gastric MALT-lymphomas, and even within the increasing subset of non-gastric localizations, have been discovered more recently. While *Helicobacter pylori* has clearly been established as a causative agent for gastric MALT lymphoma, HP-negative gastric MALT-lymphomas are becoming increasingly more common, challenging the therapeutic approach to gastric MALT-lymphoma. In addition, expanding knowledge on infections in other types of MALT-lymphoma as well as their therapeutic implications will be covered. A special focus is on novel developments in systemic therapy, especially immunotherapy, but also current concepts on radiotherapy and application of PET/CT.

---

### Guest Editor

Prof. Dr. Markus Raderer

Department of Internal Medicine I, Division of Oncology Medical,  
University of Vienna, Vienna, Austria

---

### Deadline for manuscript submissions

closed (30 November 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/69119](https://mdpi.com/si/69119)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)